Proprietary Glycoprotein Technology Platform Will Advance Lysosomal Storage Disorder Programs Excerpt from August 7, 2001 Press Release Genzyme Corp. and

Article on Transgenic EnzymeA protein that helps the body carry out chemical reactions. Replacement Therapy Enzyme therapy for pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart. with recombinant human alpha-glucosidase from rabbit milk Van den

This is an approximate transcript (i.e. from notes, not a tape) of an interview between Novazyme and the International Pompe

The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the

Excerpt from Pharming Press Release—March 30, 2001 LEIDEN, the Netherlands, March 30, 2001 – Pharming Group N.V. announced the start

Excerpt From Press Release-March 20, 2001 CAMBRIDGE, MA and LEIDEN,the Netherlands—Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., and

The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the

Excerpt From Press Release—October 5, 2000 Genzyme General and Pharming Group N.V., announced today that results from the first two

Chen focused on the phase I/II trials underway at Duke with 3 IIa infants. Average age at diagnosis is 5

Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe disease